PMID- 25857452
OWN - NLM
STAT- MEDLINE
DCOM- 20160401
LR  - 20161125
IS  - 1879-016X (Electronic)
IS  - 0163-7258 (Linking)
VI  - 152
DP  - 2015 Aug
TI  - Bivalirudin in stable angina and acute coronary syndromes.
PG  - 1-10
LID - S0163-7258(15)00078-9 [pii]
LID - 10.1016/j.pharmthera.2015.04.003 [doi]
AB  - A parenteral anticoagulant is indicated in patients with acute coronary 
      syndromes. Which anticoagulant should be preferred in each setting is not clearly 
      established. Bivalirudin administration was considered in acute coronary 
      syndromes after several clinical trials showed decreased bleeding risk with its 
      use compared with the association of unfractionated heparin (UFH) with 
      glycoprotein IIb/IIIa inhibitors (GPIs). Most recent data demonstrate that the 
      bleeding benefit identified in the previous studies was not due to bivalirudin's 
      properties but to higher bleeding incidence in the comparator arm due to the 
      disproportional use of GPIs with heparin. This paper reviews clinical evidence on 
      bivalirudin as anticoagulant in stable angina and acute coronary syndromes.
CI  - Copyright (c) 2015 Elsevier Inc. All rights reserved.
FAU - Mavrakanas, Thomas A
AU  - Mavrakanas TA
AD  - McGill University Health Center, Montreal, Canada; General Internal Medicine 
      Division, Geneva University Hospitals, Geneva, Switzerland.
FAU - Chatzizisis, Yiannis S
AU  - Chatzizisis YS
AD  - Cardiovascular Division, Brigham and Women's Hospital, Harvard Medical School, 
      Boston, USA. Electronic address: ychatzizisis@partners.org.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20150407
PL  - England
TA  - Pharmacol Ther
JT  - Pharmacology & therapeutics
JID - 7905840
RN  - 0 (Fibrinolytic Agents)
RN  - 0 (Hirudins)
RN  - 0 (Peptide Fragments)
RN  - 0 (Recombinant Proteins)
RN  - TN9BEX005G (bivalirudin)
SB  - IM
MH  - Acute Coronary Syndrome/diagnosis/*drug therapy/epidemiology
MH  - Angina, Stable/diagnosis/*drug therapy/epidemiology
MH  - Animals
MH  - Fibrinolytic Agents/*therapeutic use
MH  - Hirudins
MH  - Humans
MH  - Peptide Fragments/*therapeutic use
MH  - Randomized Controlled Trials as Topic/methods
MH  - Recombinant Proteins/therapeutic use
OTO - NOTNLM
OT  - Acute coronary syndrome
OT  - Angina
OT  - Bivalirudin
OT  - Heparin
OT  - Non-ST-elevation myocardial infarction
OT  - ST-elevation myocardial infarction
EDAT- 2015/04/11 06:00
MHDA- 2016/04/02 06:00
CRDT- 2015/04/11 06:00
PHST- 2015/03/30 00:00 [received]
PHST- 2015/03/31 00:00 [accepted]
PHST- 2015/04/11 06:00 [entrez]
PHST- 2015/04/11 06:00 [pubmed]
PHST- 2016/04/02 06:00 [medline]
AID - S0163-7258(15)00078-9 [pii]
AID - 10.1016/j.pharmthera.2015.04.003 [doi]
PST - ppublish
SO  - Pharmacol Ther. 2015 Aug;152:1-10. doi: 10.1016/j.pharmthera.2015.04.003. Epub 
      2015 Apr 7.